scholarly journals Heat Shock Proteins, Autoimmunity, and Cancer Treatment

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Stuart K. Calderwood ◽  
Mary Ann Stevenson ◽  
Ayesha Murshid

Heat shock proteins (HSPs) have been linked to the therapy of both cancer and inflammatory diseases, approaches that utilize contrasting immune properties of these proteins. It would appear that HSP family members Hsp60 and Hsp70, whether from external sources or induced locally during inflammation, can be processed by antigen-presenting cells and that HSP-derived epitopes then activate regulatory T cells and suppress inflammatory diseases. These effects also extend to the HSP-rich environments of cancer cells where elevated HSP concentrations may participate in the immunosuppressive tumor milieu. However, HSPs can also be important mediators of tumor immunity. Due to their molecular chaperone properties, some HSPs can bind tumor-specific peptides and deliver them deep into the antigen-processing pathways of antigen-presenting cells (APCs). In this context, HSP-based vaccines can activate tumor-specific immunity, trigger the proliferation and CTL capabilities of cancer-specific CD8+ T cells, and inhibit tumor growth. Further advances in HSP-based anticancer immunotherapy appear to involve improving the properties of the molecular chaperone vaccines by enhancing their antigen-binding properties and combating the immunosuppressive tumor milieu to permit programming of active CTL capable of penetrating the tumor milieu and specifically targeting tumor cells.

2007 ◽  
Vol 361-363 ◽  
pp. 1207-1210 ◽  
Author(s):  
Patrick Frayssinet ◽  
Daniel Ciocca ◽  
Nicole Rouquet

Cancer cells synthesize abnormal proteins and peptides which are associated to heat shock proteins being overproduced by these cells due to the stress induced by the particular biology of cancer tissue. We have purified on hydroxylapatite powder heat shock proteins using the HAparticles as purification bed, vectors for the proteins and vaccination adjuvant. The powder make possible that the purified HSPs and their associated peptides are transfected to the antigen presenting cells and presented to the T cells for the destruction of the cancer cells bearing the antigens.


1991 ◽  
Vol 21 (9) ◽  
pp. 2139-2143 ◽  
Author(s):  
Elisabeth Hermann ◽  
Ansgar W. Lohse ◽  
Ruurd Van Der Zee ◽  
Willem Van Eden ◽  
Werner J. Mayet ◽  
...  

2020 ◽  
pp. 557-569
Author(s):  
Willi Born ◽  
Mary Ann DeGroote ◽  
Fu Yang-Xin ◽  
Christina Ellis Roark ◽  
Kent Heyborne ◽  
...  

2020 ◽  
Author(s):  
V. Sudhakar Reddy ◽  
Trinath Jamma ◽  
G. Bhanuprakash Reddy

1996 ◽  
Vol 2 (5) ◽  
pp. 250-250
Author(s):  
M Salvetti ◽  
G Ristori ◽  
P Fiori ◽  
C Buttinelli ◽  
C Fieschi ◽  
...  

2020 ◽  
Vol 6 (40) ◽  
pp. eaba6584
Author(s):  
Tianzhen He ◽  
De Yang ◽  
Xiao-Qing Li ◽  
Mengmeng Jiang ◽  
Md Sahidul Islam ◽  
...  

CD4+Foxp3+ regulatory T cells (Tregs) are pivotal for the inhibition of autoimmune inflammatory responses. One way to therapeutically harness the immunosuppressive actions of Tregs is to stimulate the proliferative expansion of TNFR2-expressing CD4+Foxp3+ Tregs via transmembrane TNF (tmTNF). Here, we report that two-pore channel (TPC) inhibitors markedly enhance tmTNF expression on antigen-presenting cells. Furthermore, injection of TPC inhibitors including tetrandrine, or TPC-specific siRNAs in mice, increases the number of Tregs in a tmTNF/TNFR2-dependent manner. In a mouse colitis model, inhibition of TPCs by tetrandrine markedly attenuates colon inflammation by expansion of Tregs. Mechanistically, we show that TPC inhibitors enhance tmTNF levels by disrupting surface expression of TNF-α–converting enzyme by regulating vesicle trafficking. These results suggest that the therapeutic potential of TPC inhibitors is mediated by expansion of TNFR2-expressing Tregs and elucidate the basis of clinical use in the treatment of autoimmune and other inflammatory diseases.


2000 ◽  
Vol 48 (11) ◽  
pp. 653-659 ◽  
Author(s):  
M. Loui Thomas ◽  
Urmila C. Samant ◽  
Ramakant Krishnaji Deshpande ◽  
Shubhada Vivek Chiplunkar

Sign in / Sign up

Export Citation Format

Share Document